Year: 2012
Type: review
Abstract: The EUROGIN 2011 roadmap reviews the current burden of human papillomavirus (HPV)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV infection. HPV infection causes ~600,000 cases of cancer of the cervix, vulva, vagina, anus and oropharynx annually, as well as benign diseases such as genital warts and recurrent respiratory papillomatosis. Whereas the incidence of cervical cancer has been decreasing over recent decades, the incidence of anal and oropharyngeal carcinoma, for which there are no effective screening programs, has been rising over the last couple of decades. Randomized trials have demonstrated improved efficacy of HPV-based compared to cytology-based cervical cancer screening. Defining the best algorithms to triage HPV-positive women, age ranges and screening intervals are priorities for pooled analyses and further research, whereas feasibility questions can be addressed through screening programs. HPV vaccination will reduce the burden of cervical precancer and probably also of invasive cervical and other HPV-related disease in women. Recent trials demonstrated that prophylactic vaccination also protects against anogenital HPV infection, anogenital intraepithelial lesions and warts associated with vaccine types, in males; and anal HPV infection and anal intraepithelial neoplasia in MSM. HPV-related oropharyngeal cancer could be treated less aggressively because of better survival compared to cancers of the oropharynx unrelated to HPV. Key findings in the field of cervical cancer prevention should now be translated in cost-effective strategies, following an organized approach integrating primary and secondary prevention, according to scientific evidence but adapted to the local situation with particular attention to regions with the highest burden of disease.
Source: International Journal of Cancer
DOI: 10.1002/ijc.27650
Institutions: Institut Scientifique de Santé Publique, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Centers for Disease Control and Prevention, European Institute of Oncology, University of California, San Francisco, University of York, Hull York Medical School, Johns Hopkins University, Sidney Kimmel Cancer Center, United States Department of Health and Human Services, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Australian Centre for the Prevention of Cervical Cancer, Chinese Academy of Medical Sciences & Peking Union Medical College, University of Cape Town, Groote Schuur Hospital, Bar-Ilan University, Western Galilee Hospital, Hôpital Bichat-Claude-Bernard, Moffitt Cancer Center, Centre international de recherche sur le cancer
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Keywords: human papillomavirus, HPV-related diseases, cervical cancer, HPV vaccination, HPV-based cervical cancer screening, anal HPV infection, oropharyngeal cancer, anal intraepithelial neoplasia, genital warts, recurrent respiratory papillomatosis, HPV-related cancer prevention, men who have sex with men, cervical precancerous lesions
Open Access status: bronze
Awards: Role of human papillomavirus infection and other co-factors in the aetiology of head and neck cancer in India and Europe, G3698611044, health-economic modelling of PREvention strategies for Hpv-related Diseases in European CounTries, G8680805530, Human papillomavirus (HPV) infection and cervical and anal cancers
OpenAlex ID: W2103648930
